Anavex Life Sciences Corp (AVXL)

[Talon38]

Nidan, The NIH press release says the leadership of the ACTC will fall to academic and medical institutions and interface with the National Institute for Aging (NIA) and up through the NIH to the FDA:

"The ACTC will be led jointly by research teams from the University of Southern California Alzheimer’s Therapeutic Research Institute (ATRI), San Diego, Harvard-affiliated Brigham and Women’s Hospital and Massachusetts General Hospital, Boston, and Mayo Clinic, Rochester, Minnesota. The funds were awarded by the National Institute on Aging (NIA) at NIH, which leads the federal effort in Alzheimer’s research. NIA will also provide scientific input to the ACTC under the cooperative agreement."

So as much as we can trust these institutions to put science and humanity first and Scott Gottlieb and Janet Woodcock to follow the Administration marching orders to get effective, safe and economical drugs to market quickly, I think AVXL will be okay.

Again, from what I have read and seen from the FDA current leadership, I'm encouraged. The ACTC seems to be well structured organizationally and properly funded. The NIH, I believe, has a proposed budget for health research of $1.3-5B over the next 10 years with a good chunk of that going to grants.
Anavex should have a grant request into NIH if Tayo is worth his salt.

2018 will provide the "proof in the pudding".